ES2385251A1 - Adenovirus oncolíticos para el tratamiento del cáncer. - Google Patents

Adenovirus oncolíticos para el tratamiento del cáncer. Download PDF

Info

Publication number
ES2385251A1
ES2385251A1 ES200901201A ES200901201A ES2385251A1 ES 2385251 A1 ES2385251 A1 ES 2385251A1 ES 200901201 A ES200901201 A ES 200901201A ES 200901201 A ES200901201 A ES 200901201A ES 2385251 A1 ES2385251 A1 ES 2385251A1
Authority
ES
Spain
Prior art keywords
art
oncolytic
adenovirus
vol
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200901201A
Other languages
English (en)
Other versions
ES2385251B1 (es
Inventor
Sònia Guedán Carrió
Manel María Cascalló Piqueras
Ramón Alemany Bonastre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut D Investigacio Biomedica De Bell
Original Assignee
Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Institut Catala dOncologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43050014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2385251(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL, Institut Catala dOncologia filed Critical Fundacio Privada Institut dInvestigacio Biomedica de Bellvitge IDIBELL
Priority to ES200901201A priority Critical patent/ES2385251B1/es
Priority to CN201080028895XA priority patent/CN102548584A/zh
Priority to RU2011149458/10A priority patent/RU2536931C2/ru
Priority to EP10772050.0A priority patent/EP2428229B1/en
Priority to PL10772050T priority patent/PL2428229T3/pl
Priority to ES10772050.0T priority patent/ES2600955T3/es
Priority to CN201710271203.8A priority patent/CN107252438A/zh
Priority to JP2012509064A priority patent/JP2012525833A/ja
Priority to US13/318,876 priority patent/US10316065B2/en
Priority to BRPI1011445A priority patent/BRPI1011445B8/pt
Priority to MX2011011818A priority patent/MX2011011818A/es
Priority to KR1020117029097A priority patent/KR101878274B1/ko
Priority to PCT/ES2010/000196 priority patent/WO2010128182A1/es
Priority to AU2010244348A priority patent/AU2010244348B2/en
Priority to CA2761183A priority patent/CA2761183C/en
Publication of ES2385251A1 publication Critical patent/ES2385251A1/es
Priority to HK12108533.3A priority patent/HK1167818A1/zh
Publication of ES2385251B1 publication Critical patent/ES2385251B1/es
Application granted granted Critical
Priority to HK18104062.5A priority patent/HK1244679A1/zh
Priority to US16/405,285 priority patent/US20190345204A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Adenovirus oncolíticos para el tratamiento del cáncer.La invención se refiere a un adenovirus oncolítico que comprende una secuencia que codifica una enzima hialuronidasa insertada en su genoma. Este adenovirus se distribuye más eficientemente por la masa tumoral y por consiguiente se aumenta el efecto oncolítico. Inyectando el adenovirus oncolítico de la invención endovenosamente se obtienen regresiones del volumen tumoral. Por lo tanto el adenovirus oncolítico de la presente invención es útil para el tratamiento del cáncer o de un estado pre-maligno del mismo.

Claims (2)

  1. REIVINDICACIONES
    1
    OFICINA ES ANOLA DE ATENTES Y MARCAS
    N.° solicitud:
    ES ANA
    Fecha de presentaci6n de la solicitud: 6. .
    3 Fecha de prioridad:
    INFORME SOBRE EL ESTADO DE LA TECNICA
    Int. Cl. : C12N151861 ( 6. ) A61K48100 ( 6. )
    DOCUMENTOS RELEVANTES
    Categoria
    ® Documentos citados Reivindicaciones afectadas
    Y Y Y Y Y GANESH S. et al.: "Relaxin� espressing fiber chimeric oncolytic adenovirus prolongs survival of tumor�bearingmice', CANCER RES, ( 7), vol. 67, no. , 7, paginas 43 �44 7, todo el documento. KIM JO O�HANG et al .: "Relaxin e xpression f rom t umor�targeting ade noviruses and its intratumoral spread, apoptosis induction, and efficacy", JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY RESS, GB, ( 6), vol 8, n° , pag. 48 � 4 3, todo el documento. GANESH S.: "Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models", ( 8), CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 4, n° , pag. 3 33� 3 4 , todo el documento. JIN CHENG et al.: "Human Matrix Metalloproteinase 8 Gene Delivery increases the Oncolytic Activityof a Replicating Adenovirus", ( 7), MOLECULAR THERA Y, vol. �, n° , pag. 8 � , todo el documento. TOOLE B et al.: "Hyaluronan; A constitutive regulator of chemoresistance and malignancyin cancer cells", SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC UBLICATIONS, HILADEL HIA, A, US, ( 8), vol. 8, n° 4, pag. 44� � , todo el documento.
    Categoria de los documentos citados X: de particular relevancia Y: de particular relevancia combinado con otro/s de la misma categoria A: refleja el estado de la tecnica O: referido a divulgaci6n no escrita : publicado entre la fecha de prioridad yla de presentaci6n de la solicitud E: documento anterior, pero publicado despues de la fecha de presentaci6n de la solicitud
    El presente informe ha sido realizado � para todas las reivindicaciones � para las reivindicaciones n°:
    Fecha de realizaci6n del informe 3. 7. Examinador M. Hernandez Cuellar Pagina /4
    INFORME DEL ESTADO DE LA TECNICA
    N° de solicitud:
    Documentaci6n minima buscada (sistema de clasificaci6n seguido de los simbolos de clasificaci6n) C N, A6 K Bases de datos electr6nicas consultadas durante la busqueda (nombre de la base de datos y, si es posible, terminos de
    busqueda utilizados) E ODOC, W I, MEDLINE, EMBASE, BIOSIS, CA LUS
    Informe del Estado de la Tecnica agina /4
    OPINION ESCRITA
    N° de solicitud:
    Fecha de Realizaci6n de la Opini6n Escrita: 3. 7.
    Declaraci6n
    Novedad (Art. .1 LP 11/198 ) Reivindicaciones SI Reivindicaciones NO
    Actividad inventiva (Art. 8.1 LP11/198 ) Reivindicaciones SI Reivindicaciones NO
    Se considera que la solicitud cumple con el requisito de aplicaci6n industrial. Este requisito fue evaluado durante la fase de examen formal y tecnico de la solicitud (Articulo 3 . Ley / 86).
    Base de la Opini6n.-
    La presente opini6n se ha realizado sobre la base de la solicitud de patente tal y como se publica.
    Informe del Estado de la Tecnica agina 3/4
    OPINION ESCRITA
    N° de solicitud:
    1. Documentos considerados.-
    A continuaci6n se relacionan los documentos pertenecientes al estado de la tecnica tomados en consideraci6n para la realizaci6n de esta opini6n.
    Documento
    Numero Publicaci6n o Identificaci6n Fecha Publicaci6n
    D
    GANESH S. et al.: "Relaxin� espressing fiber chimeric oncolytic adenovirus prolongs survival of tumor �bearing mice', CANCER RES, ( 7), vol. 67, n o. , 7, paginas 43 �44 7, todo el documento.
    D
    KIM JOO�HANG et al.: "Relaxin expression from tumor�targeting adenoviruses and i ts intratumoral sp read, apoptosis induction, and ef ficacy", JO URNAL O F THE NATIONAL CA NCER INSTITUTE, OXFORD UNIVERSITY RESS, GB, ( 6), vol 8, n° , pag. 48 � 4 3, todo el documento.
    D 3
    GANESH S.: "Intratumoral coadministration of hyaluronidase enzyme an d oncolytic adenoviruses enhances virus potency i n metastatic tumor m odels", ( 8), C LINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 4, n° , pag. 3 33� 3 4 , todo el documento.
    D 4
    JIN CHE NG et al .: "H uman Ma trix Metalloproteinase�8 Gene Delivery i ncreases the O ncolytic Activity of a R eplicating Adenovirus", ( 7), MO LECULAR T HERA Y, vol. �, n° , pag. 8 � , todo el documento.
    D �
    TOOLE B et al.: "Hyaluronan; A constitutive regulator of chemoresistance and malignancy in cancer cells", SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC UBLICATIONS, HILADEL HIA, A, US, ( 8), vol. 8, n° 4, pag. 44�� , todo el documento.
  2. 2. Declaraci6n motivada segun los articulos 29. y 29.7 del Reglamento de ejecuci6n de la Ley 11/198 , de 20 de marzo, de Patentes sobre la novedad y la actividad inventiva; citas y explicaciones en apoyo de esta declaraci6n
    La presente invenci6n se refiere a adenovirus oncoliticos que tienen una secuencia que codifica una hialuronidasa insertada en su genoma, asi como a composiciones farmaceuticas que comprenden el citado adenovirus y su uso para la fabricaci6n de un medicamento para el tratamiento del cancer.
    .� NOVEDAD Ninguno de los documentos citados describe adenovirus oncoliticos que tienen una secuencia que codifica una hialuronidasa insertada e n s u ge noma. E n co nsecuencia l as reivindicaciones cumplen e l r equisito de nov edad establecido en el Art. 6. L / 86.
    .�ACTIVIDAD INVENTIVA Cualquiera de los documentos D y D se puede considerar representativo del estado de la tecnica mas cercano a la invenci6n. Ambos documentos describen un adenovirus oncolitico que comprende una secuencia que codifica relaxina insertada en su genoma. La diferencia entre la informaci6n aportada en ambos documentos y la reivindicaci6n es la elecci6n de la hialuronidasa como el gen expresado por el adenovirus oncolitico. El efecto de esta diferencia es el mismoque el mostrado en ambos documentos, es decir, la degradaci6n de la matriz extracelular de las celulas tumorales para facilitar la diseminaci6n del adenovirus y mejorar su eficacia. El problema subyacente de la reivindicaci6n se puede plantear como la provisi6n de un adenovirus oncolitico alternativo con el mismo prop6sito. La soluci6n que proporciona la reivindicaci6n es un adenovirus oncolitico que tienen una secuencia que codifica una hialuronidasa insertada en su genoma. El documento D � describe la capacidad de la hialuronidasa para degradar la matriz extracelular de las celulas tumorales y permitir una diseminaci6n eficiente de los adenovirus oncoliticos que mejora la actividad anti tumoral, tal y como se describe en D 3. En este sentido se considera que la capacidad de degradar la matriz extracelular asi como su posible uso para mejorar la diseminaci6n y eficacia de un adenovirus oncolitico era informaci6n accesible para un experto en la materia con anterioridad la presentaci6n de la solicitud de patente. A la vista de la mejora proporcionada por la expresi6n de una enzima que degrada la matriz extracelular por el adenovirus oncolitico en vez de la coadministraci6n de la hialuronidasa con el adenovirus oncolitico, el experto en la materia habria conseguido el objeto de la reivindicaci6n sin esfuerzo inventivo. Las reivindicaciones dependientes tambien carecen de actividad inventiva ya que corresponden a realizaciones que se consideran rutinarias en el estado de la tecnica. Finalmente, losadenovirus oncoliticos descritos en el estado de la tecnica se usan para el tratamiento del cancer. En este sentido, los usos terapeuticos de las reivindicaciones y tambien carecen de actividad inventiva. En consecuencia, las reivindicaciones no cumplen el requisito establecido en el Art. 8. L / 86.
    Informe del Estado de la Tecnica agina 4/4
ES200901201A 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer. Expired - Fee Related ES2385251B1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
ES200901201A ES2385251B1 (es) 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer.
MX2011011818A MX2011011818A (es) 2009-05-06 2010-05-05 Adenovirus oncoliticos para el tratamiento del cancer.
PCT/ES2010/000196 WO2010128182A1 (es) 2009-05-06 2010-05-05 Adenovirus oncolíticos para el tratamiento del cáncer
EP10772050.0A EP2428229B1 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
PL10772050T PL2428229T3 (pl) 2009-05-06 2010-05-05 Onkolityczne adenowirusy do leczenia raka
ES10772050.0T ES2600955T3 (es) 2009-05-06 2010-05-05 Adenovirus oncolíticos para el tratamiento del cáncer
CN201710271203.8A CN107252438A (zh) 2009-05-06 2010-05-05 用于治疗癌症的溶瘤腺病毒
JP2012509064A JP2012525833A (ja) 2009-05-06 2010-05-05 癌治療のための腫瘍溶解アデノウイルス
US13/318,876 US10316065B2 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
BRPI1011445A BRPI1011445B8 (pt) 2009-05-06 2010-05-05 Adenovírus oncolíticos para o tratamento de câncer
CN201080028895XA CN102548584A (zh) 2009-05-06 2010-05-05 用于治疗癌症的溶瘤腺病毒
KR1020117029097A KR101878274B1 (ko) 2009-05-06 2010-05-05 암 치료용 암 용해성 아데노바이러스
RU2011149458/10A RU2536931C2 (ru) 2009-05-06 2010-05-05 Онколитический аденовирус для лечения рака, его применение и фармацевтическая композиция, содержащая его
AU2010244348A AU2010244348B2 (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
CA2761183A CA2761183C (en) 2009-05-06 2010-05-05 Oncolytic adenoviruses for treating cancer
HK12108533.3A HK1167818A1 (zh) 2009-05-06 2012-08-31 用於治療癌症的溶瘤腺病毒
HK18104062.5A HK1244679A1 (zh) 2009-05-06 2018-03-23 用於治療癌症的溶瘤腺病毒
US16/405,285 US20190345204A1 (en) 2009-05-06 2019-05-07 Oncolytic adenoviruses for treating cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200901201A ES2385251B1 (es) 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer.

Publications (2)

Publication Number Publication Date
ES2385251A1 true ES2385251A1 (es) 2012-07-20
ES2385251B1 ES2385251B1 (es) 2013-05-06

Family

ID=43050014

Family Applications (2)

Application Number Title Priority Date Filing Date
ES200901201A Expired - Fee Related ES2385251B1 (es) 2009-05-06 2009-05-06 Adenovirus oncolíticos para el tratamiento del cáncer.
ES10772050.0T Active ES2600955T3 (es) 2009-05-06 2010-05-05 Adenovirus oncolíticos para el tratamiento del cáncer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10772050.0T Active ES2600955T3 (es) 2009-05-06 2010-05-05 Adenovirus oncolíticos para el tratamiento del cáncer

Country Status (14)

Country Link
US (2) US10316065B2 (es)
EP (1) EP2428229B1 (es)
JP (1) JP2012525833A (es)
KR (1) KR101878274B1 (es)
CN (2) CN107252438A (es)
AU (1) AU2010244348B2 (es)
BR (1) BRPI1011445B8 (es)
CA (1) CA2761183C (es)
ES (2) ES2385251B1 (es)
HK (2) HK1167818A1 (es)
MX (1) MX2011011818A (es)
PL (1) PL2428229T3 (es)
RU (1) RU2536931C2 (es)
WO (1) WO2010128182A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177008A1 (en) 2003-03-05 2012-01-30 Halozyme Inc Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
CN103405480B (zh) * 2013-05-03 2015-11-25 浙江理工大学 10-羟基喜树碱-丁二酸与腺病毒结合物及制法和用途
CN103614416B (zh) * 2013-09-30 2016-09-07 中国人民解放军第二军医大学东方肝胆外科医院 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途
TR201802728T4 (tr) * 2013-10-25 2018-03-21 Psioxus Therapeutics Ltd Heterolog genlerle donatılmış onkolitik adenovirüsler.
EP2940128A1 (en) 2014-04-30 2015-11-04 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Adenovirus comprising an albumin-binding moiety
EP3186281B1 (en) 2014-08-28 2019-04-10 Halozyme, Inc. Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
GB201505860D0 (en) * 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
WO2016174200A1 (en) 2015-04-30 2016-11-03 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a b7 protein
AU2016257196B2 (en) * 2015-05-04 2021-11-25 Vcn Biosciences Sl Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment
CN104946601A (zh) * 2015-05-28 2015-09-30 金宁一 重组溶瘤腺病毒及其应用
BR112018012180A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
EP3380621A4 (en) * 2016-04-22 2019-05-08 Immvira Co., Limited CONSTRUCTION OF THE VECTOR OF OBLIGATES ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CANCER THERAPY CONSTRUCTIONS
KR102443064B1 (ko) * 2016-04-29 2022-09-14 이노비오 파마수티컬즈, 인크. 제제의 전달을 향상시키기 위한 콘드로이티나제 및/또는 히알루로니다제의 생체내 용도
WO2017201635A1 (zh) * 2016-05-23 2017-11-30 蔡胜和 透明质酸酶的细胞表达及其在实体瘤细胞治疗中的应用
AU2017290828A1 (en) * 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
EP3512533B9 (en) * 2016-11-17 2021-05-19 VCN Biosciences SL Oncolytic viral vectors for use in the treatment of retinoblastoma
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
JP7277926B2 (ja) * 2017-11-08 2023-05-19 国立大学法人 鹿児島大学 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療）
CN109913422A (zh) * 2017-12-13 2019-06-21 苏州康聚生物科技有限公司 一种包含肿瘤抗原识别受体的免疫细胞及其应用
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
KR102267837B1 (ko) * 2018-01-19 2021-06-22 코오롱생명과학 주식회사 재조합 백시니아 바이러스 및 이를 포함하는 약학 조성물
WO2019174610A1 (zh) * 2018-03-14 2019-09-19 蔡立刚 一种溶瘤病毒、合成dna序列及其应用
WO2020047345A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
JP2022543445A (ja) 2019-08-05 2022-10-12 メゾブラスト・インターナショナル・エスアーエールエル ウイルスベクターを含む細胞組成物及び処置方法
CN111909962A (zh) * 2020-07-23 2020-11-10 药鼎(北京)国际细胞医学技术有限公司 一种治疗肝癌的病毒构建体及其用途和构建方法
JP2023537103A (ja) 2020-08-10 2023-08-30 メゾブラスト・インターナショナル・エスアーエールエル 細胞組成物及び治療方法
RU2753742C1 (ru) * 2020-10-16 2021-08-24 Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Рекомбинантный штамм Ad6-hTERT-GMCSF, содержащий встройку промотора теломеразы человека hTERT, а также гена гранулоцитарно-макрофагального колониестимулирующего фактора человека, обладающий избирательной цитолитической активностью против теломераза-положительных опухолевых клеток и экспрессирующий активный человеческий гранулоцитарно-макрофагальный колониестимулирующий фактор
CA3215344A1 (en) 2021-04-30 2022-11-03 Kalivir Immunotherapeutics, Inc. Oncolytic viruses for modified mhc expression
CN114703186B (zh) * 2022-03-31 2023-08-29 四川大学 肿瘤特异性启动子及其应用
WO2024062372A1 (en) * 2022-09-19 2024-03-28 Theriva Biologics, S.L. Combination therapies with oncolytic adenovirus and topoisomerase i inhibitors or prodrugs thereof
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5721348A (en) 1990-12-14 1998-02-24 University Of Connecticut DNA encoding PH-20 proteins
EP0872552A1 (en) * 1997-04-15 1998-10-21 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or Apoptin
US5516631A (en) 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
ATE178490T1 (de) 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
US5846945A (en) 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
GB9415167D0 (en) 1994-07-27 1994-09-14 Springer Caroline J Improvements relating to cancer therapy
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6326356B1 (en) 1996-10-18 2001-12-04 Board Of Regents, The University Of Texas System Suppression of neu overexpression using a mini-E1A gene
US20040048821A1 (en) 1997-06-27 2004-03-11 Cold Spring Harbor Laboratory Enhancement of drug cytotoxicity in tumor cells containing mutant Rb gene
CA2327545A1 (en) 1998-02-06 1999-08-12 Uab Research Foundation Adenovirus vector containing a heterologous peptide epitope in the hi loop of the fiber knob
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
AU758354B2 (en) 1998-10-15 2003-03-20 Canji, Inc. Selectively replicating viral vectors
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
WO2000029599A1 (en) 1998-11-18 2000-05-25 Canji, Inc. Viral vectors with late transgene expression
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
WO2000067576A1 (en) 1999-05-12 2000-11-16 The Uab Research Foundation Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
CA2380537C (en) 1999-11-15 2011-01-18 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
US7078030B2 (en) 1999-11-15 2006-07-18 Onyx Pharmaceuticals, Inc Oncolytic adenovirus
US7306902B2 (en) 2002-06-28 2007-12-11 Oncolyties Biotech Inc. Oncolytic viruses as phenotyping agents for neoplasms
AU7333701A (en) 2000-07-10 2002-01-21 Univ Texas Chromosome 3p21.3 genes are tumor suppressors
EP1203819A3 (en) 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
US7109029B2 (en) 2001-02-23 2006-09-19 Cell Genesys, Inc. Vector constructs
IL152420A0 (en) 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
JP4916641B2 (ja) 2001-05-11 2012-04-18 ウェルスタット バイオロジクス コーポレイション 腫瘍崩壊性ウイルス治療
CA2474763A1 (en) 2002-01-24 2003-07-31 The Scripps Research Institute Fiber shaft modifications for efficient targeting
WO2003072703A2 (en) 2002-02-05 2003-09-04 Cornell Research Foundation, Inc. Adenoviral vector with replication-dependent transgene expression
US7807618B2 (en) 2002-05-20 2010-10-05 The Board Of Regents Of The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone and other tissues
SG177008A1 (en) 2003-03-05 2012-01-30 Halozyme Inc Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2519680A1 (en) * 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
WO2005018332A1 (en) 2003-08-13 2005-03-03 The General Hospital Corporation Modified microorganisms for anti-cancer therapy
WO2005030927A2 (en) * 2003-09-23 2005-04-07 Uab Research Foundation Methods and compositions for in vivo inflammation monitoring
WO2005086922A2 (en) * 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US20060292682A1 (en) * 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
CA2601187A1 (en) 2005-03-09 2006-09-14 Board Of Regents, The University Of Texas System Novel htmc promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genes
WO2007059473A2 (en) * 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
CA2634591A1 (en) 2005-12-22 2007-07-05 Memorial Sloan-Kettering Cancer Center Method for detection of cancer cells using virus
EP4269578B1 (en) * 2008-03-06 2024-06-05 Halozyme, Inc. Soluble hyaluronidase composition
ES2385251B1 (es) * 2009-05-06 2013-05-06 Fundació Privada Institut D'investigació Biomèdica De Bellvitge Adenovirus oncolíticos para el tratamiento del cáncer.

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GANESH S,: ¿Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenovíruses enhances virus potency in metastatic tumor models¿, (2008), CL1NICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 14, nº 12, pág. 3933-3941, todo el documento. *
GANESH S. ET AL: ¿Relaxin- espressing fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice¿, CANCER RES, (2007), vol. 67, no. 9, 2007, pages 4399-4407, todo el documento. *
JIN CHENG ET AL: ¿Human Matrix Metalloproteinase-8 Gene Delivery increases the Oncolytic Activity of a Replicating Adenovirus¿, (2007), MOLECULAR THERAPY, vol.. 15, nº 11, pág. 1982-1990, todo el documento. *
KIM JOO- HANG ET AL; ¿Relaxin expression from tumor- targetíng adenoviruses and its intratumoral spread, apoptosís induction, and efficacy¿, JOURNAL OF THE NATIONAL CANCER INSTITUTE, OXFORD UNIVERSITY PRESS, GB, ( 2006), vol 98, nº 20, 1 pág. 1482-1493, todo el documento. *
TOOLE B P ET AL: ¿Hyaluronan; A constitutive regulator of chemoresistance and malignancy in cancer cells¿, SEMINARS IN CANCER BIOLOGY, SAUNDERS SCIENTIFIC PUBLICATIONS, PHILADELPHTA, PA, US, (2008), vol. 18, nº 4, pág. 244-250, todo el documento. *

Also Published As

Publication number Publication date
PL2428229T3 (pl) 2017-02-28
AU2010244348A1 (en) 2011-12-01
HK1167818A1 (zh) 2012-12-14
US10316065B2 (en) 2019-06-11
KR20120049185A (ko) 2012-05-16
AU2010244348B2 (en) 2016-08-11
WO2010128182A1 (es) 2010-11-11
RU2536931C2 (ru) 2014-12-27
RU2011149458A (ru) 2013-06-27
KR101878274B1 (ko) 2018-07-13
BRPI1011445B8 (pt) 2022-10-25
EP2428229B1 (en) 2016-08-03
JP2012525833A (ja) 2012-10-25
US20120148535A1 (en) 2012-06-14
CN107252438A (zh) 2017-10-17
CA2761183A1 (en) 2010-11-11
ES2385251B1 (es) 2013-05-06
ES2600955T3 (es) 2017-02-13
MX2011011818A (es) 2012-06-19
BRPI1011445A2 (pt) 2020-09-15
EP2428229A1 (en) 2012-03-14
CA2761183C (en) 2019-03-26
HK1244679A1 (zh) 2018-08-17
US20190345204A1 (en) 2019-11-14
CN102548584A (zh) 2012-07-04
BRPI1011445B1 (pt) 2022-10-04

Similar Documents

Publication Publication Date Title
ES2385251A1 (es) Adenovirus oncolíticos para el tratamiento del cáncer.
Limia et al. Emerging roles of the endoplasmic reticulum associated unfolded protein response in cancer cell migration and invasion
UY31543A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
BRPI0608297A2 (pt) composições de lipossomos
BR112015032432A2 (pt) Conjugado de oligonucleotídeo antisense, oligômero, composição farmacêutica, uso de um oligômero ou conjugado de oligonucleotídeo antisense ou composição farmacêutica, método de tratamento da hipercolesterolemia ou de distúrbios relacionados e método in vivo ou in vitro
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
BR112015005227A2 (pt) inibidores de glicosilceramida sintase
Pirola et al. The methylation status of the epigenome: its emerging role in the regulation of tumor angiogenesis and tumor growth, and potential for drug targeting
BR112015000710A8 (pt) Oligonucleotídeos para fazer uma alteração na sequência de um presente alvo de molécula de rna em uma célula viva
BR112014031788A2 (pt) composições e métodos para o tratamento de diabetes
BR112015006524A8 (pt) derivados de quinazolinona como inibidores de parp, seu processo de preparação, seu uso, medicamentos e conjunto (kit)
CL2008003022A1 (es) Composicion farmaceutica que comprende n-(3-metoxi-5-metilpirazin-2-il)-2-(4-{1,3,4-oxadiazol-2-il}fenil)piridin-3-sulfonamida con manitol y celulosa microcristalina; y uso para el tratamiento del cancer de prostata, de ovario y de vejiga, entre otros.
Workenhe et al. Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
Delgado et al. BH3-only proteins, Bmf and Bim, in autophagy
Zhu et al. High ROS Production by Celecoxib and Enhanced Sensitivity for Death Ligand-Induced Apoptosis in Cutaneous SCC Cell Lines
Linowiecka et al. Melatonin: a potential regulator of DNA methylation
Janowska et al. The genetic basis of dormancy and awakening in cutaneous metastatic melanoma
Golla et al. Photodynamic therapy combined with Bcl-2/Bcl-xL inhibition increases the Noxa/Mcl-1 ratio independent of Usp9X and synergistically enhances apoptosis in glioblastoma
Harrikari Segmental length in Finnish: Studies within a constraint-based approach.
CL2015003267A1 (es) Tratamiento eficaz de nsclc y marcador clínico predictivo de la respuesta de un tumor a un tratamiento.
Sánchez-Romero et al. Biobancos, laboratorios clínicos e investigación biomédica
Ran Tumor angiogenesis
Monção et al. Indisulam reduces viability and regulates apoptotic gene expression in pediatric high-grade glioma cells
Gil-Sánchez et al. Protocolo diagnóstico de la fotosensibilidad
Zhu et al. Inhibition of Cell Proliferation and Cell Viability by Sinecatechins in Cutaneous SCC Cells Is Related to an Imbalance of ROS and Loss of Mitochondrial Membrane Potential

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELL

Effective date: 20120220

FG2A Definitive protection

Ref document number: 2385251

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20130506

FD2A Announcement of lapse in spain

Effective date: 20210915